Literature DB >> 10881249

[11 C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology.

S Lamusuo1, A Pitkänen, L Jutila, A Ylinen, K Partanen, R Kälviäinen, H M Ruottinen, V Oikonen, K Någren, P Lehikoinen, M Vapalahti, P Vainio, J O Rinne.   

Abstract

OBJECTIVE: To detect reduced [11C]flumazenil in patients with temporal lobe epilepsy (TLE) and to relate binding to histopathology.
METHODS: The authors studied 16 patients who underwent epilepsy surgery because of drug-resistant TLE using [11C]flumazenil PET and quantitative MRI. In 12 patients, resected hippocampus was available for histologic analysis. [11C]Flumazenil binding potential (fitted BP) was assessed with the simplified reference tissue model.
RESULTS: [11C]Flumazenil fitted BP in the medial temporal lobe was reduced in all patients with abnormal hippocampal volumetry or T2 relaxometry on MRI. Fitted BP was also reduced in 46% of the patients with hippocampal volume within the normal range and in 38% of patients with less than 2 SD T2 prolongation. In all MRI-negative/PET-positive patients, the histologic analysis verified hippocampal damage. Also, [11C]flumazenil fitted BP correlated with the severity of reduced hippocampal volume, T2 prolongation, and histologically assessed neuronal loss and astrogliosis.
CONCLUSION: [11C]Flumazenil PET provides a useful tool for investigating the hippocampal damage in vivo even in patients with no remarkable hippocampal abnormalities on quantitative MRI.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10881249     DOI: 10.1212/wnl.54.12.2252

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Neuroimaging of epilepsy.

Authors:  Fernando Cendes; William H Theodore; Benjamin H Brinkmann; Vlastimil Sulc; Gregory D Cascino
Journal:  Handb Clin Neurol       Date:  2016

2.  What does flumazenil PET add to an evaluation for temporal lobectomy?

Authors:  William H Theodore
Journal:  Epilepsy Curr       Date:  2006 Jan-Feb       Impact factor: 7.500

3.  Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency.

Authors:  P L Pearl; K M Gibson; Z Quezado; I Dustin; J Taylor; S Trzcinski; J Schreiber; K Forester; P Reeves-Tyer; C Liew; S Shamim; P Herscovitch; R Carson; J Butman; C Jakobs; W Theodore
Journal:  Neurology       Date:  2009-08-11       Impact factor: 9.910

4.  Longitudinal alterations in gamma-aminobutyric acid (GABAA) receptor availability over ∼ 1 year following traumatic brain injury.

Authors:  Y Kang; K Jamison; A Jaywant; K Dams-O'Connor; N Kim; N A Karakatsanis; T Butler; N D Schiff; A Kuceyeski; S A Shah
Journal:  Brain Commun       Date:  2022-06-15

5.  Screening of Risk Factors for Poor Prognosis in Patients with Refractory Epilepsy Secondary to Encephalomalacia.

Authors:  Yinjun Zhong
Journal:  Comput Math Methods Med       Date:  2022-07-04       Impact factor: 2.809

Review 6.  Advances in neuroimaging: management of partial epileptic syndromes.

Authors:  Barbara Schäuble; Gregory D Cascino
Journal:  Neurosurg Rev       Date:  2003-08-22       Impact factor: 3.042

7.  Seizure outcomes in relation to the extent of resection of the perifocal fluorodeoxyglucose and flumazenil PET abnormalities in anteromedial temporal lobectomy.

Authors:  Milo Stanišić; Christopher Coello; Jugoslav Ivanović; Arild Egge; Torsten Danfors; John Hald; Einar Heminghyt; Marjan Makki Mikkelsen; Bård Kronen Krossnes; Are Hugo Pripp; Pål Gunnar Larsson
Journal:  Acta Neurochir (Wien)       Date:  2015-09-08       Impact factor: 2.216

8.  A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis.

Authors:  Yeona Kang; Sandra Milena Hurtado Rúa; Ulrike W Kaunzner; Jai Perumal; Nancy Nealon; Wenchao Qu; Paresh J Kothari; Timothy Vartanian; Amy Kuceyeski; Susan A Gauthier
Journal:  Mol Imaging Biol       Date:  2020-12       Impact factor: 3.488

9.  In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy.

Authors:  Lucy Vivash; Marie-Claude Gregoire; Viviane Bouilleret; Alexis Berard; Catriona Wimberley; David Binns; Peter Roselt; Andrew Katsifis; Damian E Myers; Rodney J Hicks; Terence J O'Brien; Stefanie Dedeurwaerdere
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

10.  Altered GABAA receptor density and unaltered blood-brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis.

Authors:  Femke E Froklage; Andrey Postnov; Maqsood M Yaqub; Esther Bakker; Ronald Boellaard; N Harry Hendrikse; Emile Fi Comans; Robert C Schuit; Patrick Schober; Demetrios N Velis; Jack Zwemmer; Jan J Heimans; Adriaan A Lammertsma; Rob A Voskuyl; Jaap C Reijneveld
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-19       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.